Malignancies Clinical Trials in Houston, Texas
28 recruitingHouston, Texas
Showing 1–20 of 28 trials
Recruiting
Phase 1Phase 2
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
B-cell Malignancies
AstraZeneca174 enrolled30 locationsNCT06542250
Recruiting
Phase 1Phase 2
A Phase I/II Study of CAR.70-Engineered IL15-Transduced Cord Blood-Derived NK Cells With TGF-beta Receptor 2 (TGFBR2) Knock Out in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Myeloid Malignancies
Myeloid Malignancies
M.D. Anderson Cancer Center42 enrolled1 locationNCT06930651
Recruiting
Phase 1Phase 2
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Hematologic Malignancies
Sellas Life Sciences Group160 enrolled25 locationsNCT04588922
Recruiting
Phase 2
Optimized Cord Blood Transplantation for the Treatment of Patients With High-risk Hematologic Malignancies Who Have Relapsed After First Allogeneic Stem Cell Transplantation
Hematologic Malignancies
M.D. Anderson Cancer Center35 enrolled1 locationNCT06807606
Recruiting
Phase 2
PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)
Hematologic MalignanciesHematopoietic Stem Cell Transplant (HSCT)
Pulmotect, Inc.100 enrolled11 locationsNCT06665100
Recruiting
Phase 1
A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
Hematologic MalignanciesSolid Malignancies
Immunome, Inc.117 enrolled13 locationsNCT06823167
Recruiting
Phase 1
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Solid TumorsHematologic Malignancies
Incyte Corporation280 enrolled22 locationsNCT07195916
Recruiting
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Hematologic MalignanciesInherited Disorders of MetabolismInherited Abnormalities of Platelets+2 more
Center for International Blood and Marrow Transplant Research99,999 enrolled142 locationsNCT01351545
Recruiting
Phase 1
A Study of an IDH1m Inhibitor in Participants With IDH1-Mutated Malignancies and Hepatic or Renal Impairment
IDH1-Mutated Malignancies
Servier Bio-Innovation LLC30 enrolled19 locationsNCT07006688
Recruiting
Phase 1
A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies
Solid Tumor Malignancies
Kumquat Biosciences Inc.78 enrolled12 locationsNCT07207707
Recruiting
Phase 1Phase 2
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
Advanced Solid Malignancies
AstraZeneca695 enrolled33 locationsNCT05417594
Recruiting
Phase 1
A Study to Investigate the Safety and Efficacy of KQB168 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
Solid Tumor Malignancies
Kumquat Biosciences Inc.84 enrolled15 locationsNCT06994806
Recruiting
Phase 1
Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies
Advanced Malignancies With Homologous Recombination Deficiency (HRD) (Breast, Ovarian, mCRPC, Brain Metastases)
Duke Street Bio Ltd90 enrolled13 locationsNCT06458712
Recruiting
Phase 1
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors
Esophageal CancerProstate CancerLung Cancer (NSCLC)+1 more
Phrontline Biopharma200 enrolled7 locationsNCT07181473
Recruiting
Phase 2
Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies
SMARCB1-Deficient Malignancies
M.D. Anderson Cancer Center40 enrolled1 locationNCT06444880
Recruiting
Phase 1Phase 2
Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid Malignancies
Myeloid MalignanciesLymphodepleting Chemotherapy
M.D. Anderson Cancer Center44 enrolled1 locationNCT06383572
Recruiting
Phase 1
Radiologic Pathologic Correlation of Imaging to Distinguish True Progression From Pseudoprogression in Brain Malignancies
Brain MalignanciesPseudoprogression
M.D. Anderson Cancer Center25 enrolled1 locationNCT06199479
Recruiting
Phase 1
UBX-303061 in Subjects With Relapsed/Refractory B-Cell Malignancies
Relapsed/Refractory B-cell Malignancies
Ubix Therapeutics, Inc.94 enrolled11 locationsNCT06590961
Recruiting
Phase 1
A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors With or Without Brain Metastases
Brain Metastases From Solid TumorsSolid Tumor Malignancies
A2A Pharmaceuticals Inc.86 enrolled5 locationsNCT06136884
Recruiting
Phase 1
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
Myelodysplastic SyndromesRelapsed or Refractory Acute Myeloid Leukemia (AML)Untreated AML+1 more
Institut de Recherches Internationales Servier291 enrolled30 locationsNCT02074839